Overview
KVUE market data
Price History
KVUE price chart
Valuation & Profitability
- P/E (TTM)
- 22.64 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.76 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 437.8% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.02 – $22.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $36.7K · P/B 3.06 · P/S 2.40.
Company news
FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen SodiumBenzinga · Jul 24, 2026, 6:05 PM
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing ItThe Motley Fool · Jul 24, 2026, 3:15 PM
FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain ReliefBenzinga · Jul 24, 2026, 2:49 PM
Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $19Benzinga · Jul 21, 2026, 1:21 PM
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?The Motley Fool · Jul 20, 2026, 11:01 AM
UBS Maintains Neutral on Kenvue, Raises Price Target to $20Benzinga · Jul 16, 2026, 5:58 PM
U.S. Appeals Court Revives Private Lawsuits Linking Tylenol Painkiller To Autism, ADHDBenzinga · Jul 13, 2026, 2:42 PM
Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.The Motley Fool · Jul 13, 2026, 11:00 AM
This 4.5%-Yielding Dividend Stock Is Beating the S&P 500 and the Nasdaq. 3 Reasons That Can Continue in the Second Half of 2026The Motley Fool · Jul 8, 2026, 1:15 PM
Watching Kimberly-Clark, Kenvue; Traders Circulate Unconfirmed Report Suggesting 'China's Antirust Authority (SAMR) Is Taking A Very Close Look At The KMB/KVUE Deal, According To Sources; The Increased Scrutiny Will Lead To A Delay In Closing Or A Blocking Of The Deal, Chinese Regular Has Received A Lot Of Formal Complaints About The Deal'Benzinga · May 29, 2026, 3:25 PM